Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death ligand 1 (PD-L1)-positive previously untreated advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Koichi, Kishino, Yasunari, Homma, Tetsuya, Kusumoto, Sojiro, Yamaoka, Toshimitsu, Tanaka, Akihiko, Ohmori, Tohru, Ohnishi, Tsukasa, Sagara, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409193/
https://www.ncbi.nlm.nih.gov/pubmed/32679702
http://dx.doi.org/10.3390/cancers12071905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409193/
https://www.ncbi.nlm.nih.gov/pubmed/32679702
http://dx.doi.org/10.3390/cancers12071905

Ejemplares similares